pemoline has been researched along with Disorders of Excessive Somnolence in 3 studies
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.
pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors present five case reports illustrating that 10-20 mg of protriptyline in a single dose at bedtime can effectively control arousal dysfunction (sleep drunkenness and hypersomnia) and the narcolepsycataplexy syndrome without the apparent development of tolerance and without the side effects that are frequent complications of treatment with other agents." | 7.65 | Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. ( Clark, RW; Hyman, PR; Schmidt, HS, 1977) |
| "The authors present five case reports illustrating that 10-20 mg of protriptyline in a single dose at bedtime can effectively control arousal dysfunction (sleep drunkenness and hypersomnia) and the narcolepsycataplexy syndrome without the apparent development of tolerance and without the side effects that are frequent complications of treatment with other agents." | 3.65 | Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. ( Clark, RW; Hyman, PR; Schmidt, HS, 1977) |
| "Excessive daytime sleepiness and abnormal sleep-wake patterns are becoming increasingly pervasive in modern society." | 1.32 | Pharmacologic management of daytime sleepiness. ( Schwartz, JR, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwartz, JR | 1 |
| Littner, M | 1 |
| Schmidt, HS | 1 |
| Clark, RW | 1 |
| Hyman, PR | 1 |
3 other studies available for pemoline and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Pharmacologic management of daytime sleepiness.
Topics: Amphetamines; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnol | 2004 |
Sleep practitioners need to be aware of new changes in the labeling of pemoline (CYLERT)
Topics: Attention Deficit Disorder with Hyperactivity; Awareness; Central Nervous System Stimulants; Disorde | 1999 |
Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia.
Topics: Adult; Cataplexy; Dibenzocycloheptenes; Disorders of Excessive Somnolence; Dreams; Drug Therapy, Com | 1977 |